Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Gene mutation test

PROVIDER: PRJNA1060499 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27406315_1.fastq.gz	Fastqsanger.gz
	SRR27406315_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Based on spectrum to detect ctDNA and its application on the CRC diagnosis and prognosis

Project description:Interventions: Gold Standard:;Index test: Primary outcome(s): gene mutation Study Design: Diagnostic test for accuracy

| 2661910 | ecrin-mdr-crc

Clinical trial of Human BRAF Gene V600E Mutation Diagnostic kit (Fluorescence PCR Analysis)

Project description:Interventions: Gold Standard:Fluorescence PCR Analysis;Index test:Human BRAF Gene V600E Mutation Diagnostic kit (Fluorescence PCR Analysis) Primary outcome(s): colorectal cancer;cancerous goiter Study Design: Diagnostic test for accuracy

| 2676654 | ecrin-mdr-crc

Somatic point mutation calling in low cellularity tumors

Project description:Illumina 1M Omni Quad arrays were used to test mutation calling accuracy of qSNP tool (a mutation caller) Ilumina array genotypes with GenCal (GC score)>0.70 were used in the comparison of genotype calls using next generation sequencing data and qSNP (mutation caller)

2014-06-13 | GSE47904 | GEO

Clinical validation study of RAKSET-B, a multiple detection kit for BRAF and RAS gene mutations in colorectal cancer

Project description:Primary outcome(s): BRAF gene mutation* - Overall concordance rate, positive concordance rate, and negative concordance rate of BRAF gene mutations between standard genetic testing such as sanger sequencing and RASKET-B kit RAS gene mutation** - Overall concordance rate, positive concordance rate, and negative concordance rate of RAS gene mutations between MEBGEN RASKET KIT (an established in vitro diagnostic (IVD) kit for detecting RAS mutations) and RASKET-B kit *BRAF gene mutation codon 600 (p.V600E) **RAS gene mutation codon 12, 13, 59, 61, 117, 146

| 2637999 | ecrin-mdr-crc

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Project description:Analysis of gene expression profiles from sporadic and hereditary primary melanomas. The hypothesis was to test whether any gene expression differences exist between melanomas from CDKN2A mutation carriers and sporadic melanomas.

2014-12-31 | GSE57715 | GEO

Teleogryllus oceanicus (field cricket) wing bud proteomics

Project description:In Hawaii, a rapidly-evolving mutation in the field cricket Teleogryllus oceanicus silences males by interfering with the development of sound-producing structures on their forewings. The mutation is called flatwing (fw), and it persists because of natural selection imposed by an acoustically-orienting parasitoid. We examined gene expression differences between wild-type and mutant crickets, focusing on juvenile wing buds. We profiled mRNA expression levels using RNA-seq, and characterized the wing bud proteome using quantitative mass spectrometry. Accessing protein expression profiles under the same experimental conditions enabled us to test correspondence between the two ‘omic levels.

2016-04-06 | PXD002417 | Pride

The combination human 13 gene mutation Detection kit (reversible terminal termination sequencing) complements the clinical trial

Project description:Interventions: Gold Standard:Comparison methods :(1) comparison of similar kits;(2) Sequencing method;Index test:Human 13 gene mutation Combination Detection Kit (reversible terminal termination sequencing method) Primary outcome(s): Lung and gastrointestinal tumor genes Study Design: Sequential

| 2696826 | ecrin-mdr-crc

Sun2018 - Instantaneous mutation rate in cancer initiation and progression

Project description:Background Cancer is one of the leading causes for the morbidity and mortality worldwide. Although substantial studies have been conducted theoretically and experimentally in recent years, it is still a challenge to explore the mechanisms of cancer initiation and progression. The investigation for these problems is very important for the diagnosis of cancer diseases and development of treatment schemes. Results To accurately describe the process of cancer initiation, we propose a new concept of gene initial mutation rate based on our recently designed mathematical model using the non-constant mutation rate. Unlike the widely-used average gene mutation rate that depends on the number of mutations, the gene initial mutation rate can be used to describe the initiation process of a single patient. In addition, we propose the instantaneous tumour doubling time that is a continuous function of time based on the non-constant mutation rate. Our proposed concepts are supported by the clinic data of seven patients with advanced pancreatic cancer. The regression results suggest that, compared with the average mutation rate, the estimated initial mutation rate has a larger value of correlation coefficient with the patient survival time. We also provide the estimated tumour size of these seven patients over time. Conclusions The proposed concepts can be used to describe the cancer initiation and progression for different patients more accurately. Since a quantitative understanding of cancer progression is important for clinical treatment, our proposed model and calculated results may provide insights into the development of treatment schemes and also have other clinic implications.

2024-09-02 | BIOMD0000000915 | BioModels

Proteomics of hepatocyte like cells differentiated from iPS cells

Project description:Proteomics and phosphoproteomics in hepatocyte like cells differentiated from iPS cells with gene mutation of V30M or Y114C.

2024-11-22 | PXD047155 | JPOST Repository

test

Project description:test test

| PRJEB44966 | ENA